Table 1. U.S. Mongenic Diabetes Registry Participants Selected for GCK Testing.

	GCK-positive Subjects	GCK-negative Probands
n	157 (82 probands)	53
Female	85 (54.1%)	33 (62.3%)
Birth weight	3062g (2839-3374g)	3333g (2910-3520g)
HbA1c prior to genetic testing	6.4% (6.2-6.7%) / 46 mmol/mol (44-50 mmol/mol)	6.1% (5.9-6.4%) / 43 mmol/mol (41-46 mmol/mol)
HbA1c post genetic diagnosis	6.3% (6.1-6.5) / 45 mmol/mol (43-48)	n/a
Pharmacotherapy (>3 months duration)
None/ Not reported	80 (51.0%)	38 (71.7%)
At least one agent	77 (49.0%)	15 (28.3%)
More than one agent	20 (12.7%)	2 (3.8%)
Metformin	38 (24.2%)	4 (11.3%)
Insulin	33 (21.0%)	5 (9.4%)
Sulfonylurea	17 (10.8%)	3 (5.7%)
Proband age at hyperglycemia diagnosis	14.0 yrs (7.3-26.8yrs)	23.2 yrs. (10.0-31.8 yrs)
Proband time to genetic diagnosis	2.8 yrs (1.1- 6.2 yrs)	n/a
Proband's supervising clinician
Pediatric Endocrinologist	34 (41.4%)	24 (45.3%)
Adult Endocrinologist	28 (34.2%)	26 (49.0%)
Family Medicine	8 (9.8%)	2 (3.8%)
Internist	5 (6.1%)	1 (1.9%)
Pediatrician	5 (6.1%)	0
Obstetrician	2 (2.4%)	0

Data are median (interquartile range), n (%).